Antithrombin therapy for elective percutaneous coronary intervention: which agent to use? Does it matter?

JACC Cardiovasc Interv. 2009 Nov;2(11):1092-4. doi: 10.1016/j.jcin.2009.09.001.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Angioplasty, Balloon, Coronary* / adverse effects
  • Angioplasty, Balloon, Coronary* / mortality
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Enoxaparin / administration & dosage*
  • Enoxaparin / adverse effects
  • Fibrinolytic Agents / administration & dosage*
  • Fibrinolytic Agents / adverse effects
  • Hemorrhage / etiology
  • Hemorrhage / mortality
  • Heparin / administration & dosage*
  • Heparin / adverse effects
  • Humans
  • Injections, Intravenous
  • Myocardial Infarction / etiology
  • Myocardial Infarction / mortality
  • Patient Selection
  • Platelet Aggregation Inhibitors / therapeutic use
  • Practice Guidelines as Topic
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Anticoagulants
  • Enoxaparin
  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
  • Heparin